YM BioSciences appoints Dr. Nick Glover as President and Chief Operating Officer

07-Jun-2010 - Canada

YM BioSciences Inc. announced the appointment of Dr. Nick Glover to the newly created position of President and Chief Operating Officer. Dr. Glover will provide broad leadership to the Company and have primary responsibility for its operations and infrastructure, in particular the development and commercialization of YM's pipeline.

Dr. Glover was formerly the President and Chief Executive Officer at Viventia Biotech Inc., a biopharmaceutical company involved in the discovery and development of monoclonal antibody-based technologies for the treatment of cancer. While at Viventia, Dr. Glover led the strategic development of a novel monoclonal antibody discovery platform, advancing three clinical products including a Phase III antibody for the treatment of advanced head and neck cancer. He has been responsible for all aspects of biotherapeutic development, including GMP manufacturing, and has taken products from discovery, through preclinical development and into global registrational clinical trials, with a specific focus in oncology.

In addition to his operational experience, Dr. Glover has a significant background in business development, concluding numerous licensing and partnering agreements in both academia and industry, with organizations such as the University of Cambridge, Micromet AG and Merck KGaA. Prior to joining Viventia, Dr. Glover was an investment manager for a leading venture capital firm. Dr. Glover holds a B.Sc. (Hons) in Chemistry from the University of East Anglia, U.K., a M.Sc. in Chemistry from the University of British Columbia, Canada, and Ph.D. in Chemistry from Simon Fraser University, Canada.

https://www.bionity.com/en/news/118568/ym-biosciences-appoints-dr-nick-glover-as-president-and-chief-operating-officer.html